Syncom Formulations (India) Limited (NSE:SYNCOMF)

India flag India · Delayed Price · Currency is INR
17.95
-0.09 (-0.50%)
Sep 12, 2025, 3:30 PM IST
-0.50%
Market Cap16.93B
Revenue (ttm)4.95B
Net Income (ttm)575.57M
Shares Outn/a
EPS (ttm)0.65
PE Ratio29.41
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,066,902
Average Volume594,349
Open18.45
Previous Close18.04
Day's Range17.82 - 18.70
52-Week Range14.10 - 26.80
Beta1.31
RSI60.77
Earnings DateNov 14, 2025

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, an... [Read more]

Sector Healthcare
Founded 1988
Employees 998
Stock Exchange National Stock Exchange of India
Ticker Symbol SYNCOMF
Full Company Profile

Financial Performance

In 2024, NSE:SYNCOMF's revenue was 4.65 billion, an increase of 76.55% compared to the previous year's 2.63 billion. Earnings were 494.35 million, an increase of 95.28%.

Financial Statements

News

There is no news available yet.